Mersana Therapeutics CEO Anna Protopapas' 2018 pay jumps 184% to $2.6M
Mersana Therapeutics reports 2018 executive compensation
By ExecPay News
Published: April 23, 2019
Mersana Therapeutics reported fiscal year 2018 executive compensation information on April 23, 2019.
In 2018, four executives at Mersana Therapeutics received on average a compensation package of $1.6M, a 146% increase compared to previous year.
Average pay of disclosed executives at Mersana Therapeutics
Anna Protopapas, Chief Executive Officer, received $2.6M in total, which increased by 184% compared to 2017. 72% of Protopapas' compensation, or $1.9M, was in option awards. Protopapas also received $206K in non-equity incentive plan, $515K in salary, as well as $6K in other compensation.
David Spellman, Chief Financial Officer, received a compensation package of $1.8M. 78% of the compensation package, or $1.4M, was in option awards.
Timothy B. Lowinger, Chief Scientific Officer, earned $1.1M in 2018, a 103% increase compared to previous year.
Michael Kaufman, Chief Manufacturing Officer, received $952K in 2018.
Related executives
You may also like
Source: SEC filing on April 23, 2019.